Literature DB >> 21666220

Global eradication of measles: an epidemiologic and economic evaluation.

Ann Levin1, Colleen Burgess, Louis P Garrison, Chris Bauch, Joseph Babigumira, Emily Simons, Alya Dabbagh.   

Abstract

BACKGROUND: Measles remains an important cause of morbidity and mortality in children in developing countries. Due to the success of the measles mortality reduction and elimination efforts thus far, the WHO has raised the question of whether global eradication of measles is economically feasible.
METHODS: The cost-effectiveness of various measles mortality reduction and eradication scenarios was evaluated vis-à-vis the current mortality reduction goal in six countries and globally. Data collection on costs of measles vaccination were conducted in six countries in four regions: Bangladesh, Brazil, Colombia, Ethiopia, Tajikistan, and Uganda. The number of measles cases and deaths were projected from 2010 to 2050 using a dynamic, age-structured compartmental model. The incremental cost-effectiveness ratios were then calculated for each scenario vis a vis the baseline.
RESULTS: Measles eradication by 2020 was the found to be the most cost-effective scenario, both in the six countries and globally. Eradicating measles by 2020 is projected to cost an additional discounted $7.8 billion and avert a discounted 346 million DALYs between 2010 and 2050.
CONCLUSIONS: In conclusion, the study found that, compared to the baseline, reaching measles eradication by 2020 would be the most cost-effective measles mortality reduction scenario, both for the six countries and on a global basis.
© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666220     DOI: 10.1093/infdis/jir096

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Economic considerations for the eradication endgame.

Authors:  Scott Barrett
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

2.  Sustained Responses to Measles Revaccination at 24 Months in HIV-infected Children on Antiretroviral Therapy in Kenya.

Authors:  Laura P Newman; Anne Njoroge; Amalia Magaret; Bhavna H Chohan; Veronicah W Gitomea; Anna Wald; Jonathan Gorstein; Julie Overbaugh; Dalton Wamalwa; Elizabeth Maleche-Obimbo; Ruth Nduati; Carey Farquhar
Journal:  Pediatr Infect Dis J       Date:  2017-12       Impact factor: 2.129

3.  Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.

Authors:  Hagai Levine; Salman Zarka; Omer E Ankol; Vladi Rozhavski; Nadav Davidovitch; Yair Aboudy; Ran D Balicer
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination.

Authors:  Emily A Voigt; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Beth R Larrabee; Daniel J Schaid; Gregory A Poland
Journal:  Vaccine       Date:  2016-08-30       Impact factor: 3.641

5.  A microneedle patch containing measles vaccine is immunogenic in non-human primates.

Authors:  Chris Edens; Marcus L Collins; James L Goodson; Paul A Rota; Mark R Prausnitz
Journal:  Vaccine       Date:  2015-03-12       Impact factor: 3.641

6.  Measles vaccination using a microneedle patch.

Authors:  Chris Edens; Marcus L Collins; Jessica Ayers; Paul A Rota; Mark R Prausnitz
Journal:  Vaccine       Date:  2012-10-05       Impact factor: 3.641

7.  Bats host major mammalian paramyxoviruses.

Authors:  Jan Felix Drexler; Victor Max Corman; Marcel Alexander Müller; Gael Darren Maganga; Peter Vallo; Tabea Binger; Florian Gloza-Rausch; Veronika M Cottontail; Andrea Rasche; Stoian Yordanov; Antje Seebens; Mirjam Knörnschild; Samuel Oppong; Yaw Adu Sarkodie; Célestin Pongombo; Alexander N Lukashev; Jonas Schmidt-Chanasit; Andreas Stöcker; Aroldo José Borges Carneiro; Stephanie Erbar; Andrea Maisner; Florian Fronhoffs; Reinhard Buettner; Elisabeth K V Kalko; Thomas Kruppa; Carlos Roberto Franke; René Kallies; Emmanuel R N Yandoko; Georg Herrler; Chantal Reusken; Alexandre Hassanin; Detlev H Krüger; Sonja Matthee; Rainer G Ulrich; Eric M Leroy; Christian Drosten
Journal:  Nat Commun       Date:  2012-04-24       Impact factor: 14.919

Review 8.  Can Economic Analysis Contribute to Disease Elimination and Eradication? A Systematic Review.

Authors:  Elisa Sicuri; David B Evans; Fabrizio Tediosi
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

9.  Supplementary immunization activities (SIAs) in South Africa: comprehensive economic evaluation of an integrated child health delivery platform.

Authors:  Stéphane Verguet; Waasila Jassat; Melanie Y Bertram; Stephen M Tollman; Christopher J L Murray; Dean T Jamison; Karen J Hofman
Journal:  Glob Health Action       Date:  2013-03-01       Impact factor: 2.640

10.  Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.

Authors:  Iana H Haralambieva; Whitney L Simon; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  Viruses       Date:  2015-03-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.